Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02391402 · ClinicalTrials.gov registry record · NA

Cognitively Augmented Behavioral Activation for Veterans With Comorbid TBI/PTSD

A NA study of Post Traumatic Stress Disorder and Traumatic Brain Injury, sponsored by VA Office of Research and Development.

Completed
Registry status
NA
Development phase
73
Enrollment target
2
Study locations

NCT02391402: Completed NA study of Post Traumatic Stress Disorder and Traumatic Brain Injury, sponsored by VA Office of Research and Development.

NCT02391402 is a NA study of Post Traumatic Stress Disorder and Traumatic Brain Injury that has completed, run by VA Office of Research and Development. The registered enrollment target is 73 participants, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02391402, a NA study of Post Traumatic Stress Disorder and Traumatic Brain Injury, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
NA
Development phase
73 participants
Enrollment target
2
Study locations

Study Summary

The primary objective of this study is to evaluate the efficacy of Cognitively Augmented Behavioral Activation (CABA), a new hybrid treatment for Veterans diagnosed with comorbid mild Traumatic Brain Injury (mTBI) and posttraumatic stress disorder (PTSD). The study's specific goals are to determine whether: 1) CABA reduces PTSD symptoms in Veterans with mTBI/PTSD, 2) CABA reduces cognitive-related functional impairment in Veterans with mTBI/PTSD, 3) CABA results in improvements in depression symptoms, cognitive functioning, and quality of life in Veterans with mTBI/PTSD; and 4) CABA is an acceptable treatment for Veterans with mTBI/PTSD. The overall goal is to develop an evidence-based manualized treatment for comorbid mTBI/PTSD that can be readily implemented in Veterans Health Administration (VHA) treatment settings.

Primary Outcome

The Clinician Administered PTSD Scale (CAPS-IV; Blake et al., 1995; Weathers, Keane, \& Davidson, 2001) was used to assess initial PTSD diagnosis (DSM-IV; APA, 2000) and PTSD symptom severity across assessment time points. The CAPS is considered a "gold standard" for assessing PTSD. Items are ranked on Likert scales according to both frequency (0-4) and intensity of symptoms (0-4), yielding an overall severity score based on the sum of frequency and intensity ratings across 17 items (range 0-136

Conditions Studied

Post Traumatic Stress Disorder Traumatic Brain Injury

Interventions

  • BEHAVIORAL Treatment as Usual
  • BEHAVIORAL Cognitively Augmented Behavioral Activation

Study Locations (2)

Oregon

  • VA Portland Health Care System, Portland, OR - Portland

Washington

  • VA Puget Sound Health Care System Seattle Division, Seattle, WA - Seattle

Trial Details

FieldValue
Enrollment Target 73 participants
Start Date 2015-05-04
Est. Completion 2023-09-30
Phase NA
VA Office of Research and Development

1,668 total trials

What the finished NCT02391402 record still lists

NCT02391402 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (89% lower).

The record links to 2 conditions, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 2 interventions - of which Treatment as Usual is the first listed.

NCT02391402 reports a single indexed study location in Oregon, Washington.

Frequently Asked Questions

What is clinical trial NCT02391402 about?

NCT02391402 is a clinical study titled "Cognitively Augmented Behavioral Activation for Veterans With Comorbid TBI/PTSD". The primary objective of this study is to evaluate the efficacy of Cognitively Augmented Behavioral Activation (CABA), a new hybrid treatment for Veterans diagnosed with comorbid mild Traumatic Brain Injury (mTBI) and posttraumatic stress disorder (PTSD). The study's specific goals are to determine ...

What is the current status of trial NCT02391402?

This trial is currently completed. It is a NA study. The enrollment target is 73 participants. The study started on 2015-05-04. Estimated completion is 2023-09-30.

What conditions does trial NCT02391402 study?

This clinical trial studies the following conditions: Post Traumatic Stress Disorder, Traumatic Brain Injury.

What interventions are being tested in trial NCT02391402?

The interventions under investigation include: Treatment as Usual (BEHAVIORAL), Cognitively Augmented Behavioral Activation (BEHAVIORAL).

Who is sponsoring clinical trial NCT02391402?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02391402 being conducted?

This trial has 2 study locations across Oregon, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Post Traumatic Stress Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02391402's enrollment target sits among peer trials

73 149th of 262 higher than 113 of 262 other Post Traumatic Stress Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03661307 · 73 participants · Phase 1

    Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

  • NCT05386108 · 73 participants · Phase 1

    Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

  • NCT05961592 · 73 participants · Phase 1

    R-2487 in Patients With Rheumatoid Arthritis

  • NCT06150664 · 73 participants · Phase 1

    A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02391402, the US trial registry maintained by the National Library of Medicine. NCT02391402 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.